| Literature DB >> 15471549 |
Elmar Saathoff1, Annette Olsen, Pascal Magnussen, Jane D Kvalsvig, Wilhelm Becker, Chris C Appleton.
Abstract
BACKGROUND: Schistosomiasis is one of the major health problems in tropical and sub-tropical countries, with school age children usually being the most affected group. In 1998 the Department of Health of the province of KwaZulu-Natal established a pilot programme for helminth control that aimed at regularly treating primary school children for schistosome and intestinal helminth infections. This article describes the baseline situation and the impact of treatment on S. haematobium infection in a cohort of schoolchildren attending grade 3 in a rural part of the province.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15471549 PMCID: PMC524490 DOI: 10.1186/1471-2334-4-40
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Figure 1Location of the study area in northern KwaZulu-Natal.
Figure 2Map of the study area.
Figure 3Long-term monthly averages of rainfall and temperature in the area. Data from 1966 to 1990 for Makatini research station, about 30 km south of the study area [36].
Age and sex of the study population and prevalence and intensity of Schistosoma haematobium infection at baseline
| n = | Males 510 | Females 599 | Male/Female Ratio | 95%CI or |
| Median age (inter-quartile range) | 11.3 (9.8–12.2) | 10.7 (9.7–11.5) | - | - |
| Prevalence (%) | 65.9 | 70.3 | 0.937 | 0.864–1.017 |
| Age adjusted prevalence ratio* | - | - | 0.896 | 0.828–0.969 |
| Prevalence of infections >= 50EPC in % | 36.7 | 39.6 | 0.927 | 0.797–1.078 |
| Geometric mean EPC incl. uninfected | 14.3 | 17.8 | 0.805 |
*Mantel-Haenszel age adjusted male/female prevalence ratio
†Two-sided P-value of two samples Wilcoxon ranksum test with ties
Schistosoma haematobium prevalence and infection intensity, cure rates and egg reduction rates at various periods after treatment with 40 mg/kg praziquantel
| Weeks since treatment | Pre-treatment | 3 | 16 | 41 | 53 |
| Time of survey | Mar '98 | May/Jun | Aug | Feb '99 | Apr/May |
| n = | 1109 | 977 | 922 | 848 | 825 |
| First specimen only* | |||||
| Prevalence (%) | 68.3 | 28.8 | 18.7 | 13.2 | 20.1 |
| Cure rate (%) | - | 57.9 | 72.7 | 80.7 | 70.5 |
| Prevalence of infections >= 50 EPC (%) | 38.2 | 2.3 | 2.1 | 1.9 | 4.1 |
| Cure rate of infections >= 50 EPC (%) | - | 94.1 | 94.6 | 95.1 | 89.2 |
| Geometric mean EPC incl. uninfected | 16.1 | 0.8 | 0.4 | 0.3 | 0.6 |
| Egg reduction rate (%) | - | 95.3 | 97.5 | 97.9 | 96.0 |
| Both specimens† | |||||
| Prevalence (%) | - | 39.9 | 29.3 | 17.6 | 28.7 |
| Prevalence of infections >= 50 EPC (%) | - | 2.5 | 2.1 | 1.9 | 5.0 |
| Geometric mean EPC incl. uninfected | - | 0.9 | 0.5 | 0.3 | 0.6 |
*Results obtained when utilising only the first of two specimens that were collected
†Results obtained when utilising both specimens that were collected
Figure 4. Prevalence of infections >= any intensity threshold of interest can be read from the percentage scale. The intersection of each graph with the y-axis corresponds to the total prevalence. For the number of participants in each survey see Table 2.
Figure 5Prevalence of . Re-infection data only include children who were found egg-negative in at least one of the surveys at 3, 16 or 41 weeks after treatment. The table below the graph shows the number of participants in each age/sex stratum.